Overview
BLTE market data
Price History
BLTE price chart
Valuation & Profitability
- P/E (TTM)
- — Trailing twelve-month price-to-earnings ratio. Higher means the market is pricing in more growth. Negative or missing when earnings are negative.
- Forward P/E
- — P/E based on consensus forward EPS estimates. Lower versus trailing implies expected earnings growth.
- EPS (TTM)
- -$2.31 Diluted earnings per share over the trailing twelve months.
- Beta
- -1.20 Volatility relative to the index. 1.00 equals market, above 1 amplifies the broad-market move, below 1 dampens it.
- Dividend Yield
- — Annual dividend per share divided by current price. Zero or blank when the company does not pay a dividend.
- Profit Margin
- — Net income divided by revenue. Comparable within a sector, less so across sectors.
- 52w range
- $60.00 – $200.00 Lowest and highest closing prices over the past 52 weeks.
- Analyst Target
- — Mean of sell-side analyst 12-month price targets. Use as a sentiment gauge; targets are biased upward in aggregate.
Display-only. Refreshed once per symbol per 24 hours · market cap $7.2B · P/B 7.28.
Company News
Morgan Stanley Maintains Overweight on Belite Bio, Raises Price Target to $206Benzinga · Aug 14, 2026, 6:03 PM
Cantor Fitzgerald Maintains Overweight on Belite Bio, Raises Price Target to $270Benzinga · Aug 14, 2026, 11:03 AM
Full Transcript: Belite Bio Q2 2026 Earnings CallBenzinga · Aug 13, 2026, 8:53 PM
Belite Bio Q2 Adj. EPS $(0.54) Beats $(0.79) EstimateBenzinga · Aug 13, 2026, 7:08 AM
CoreWeave To Rally Around 95%? Here Are 10 Top Analyst Forecasts For WednesdayBenzinga · Aug 12, 2026, 11:53 AM
HC Wainwright & Co. Maintains Buy on Belite Bio, Raises Price Target to $214Benzinga · Aug 12, 2026, 11:36 AM
Belite Bio Announces FDA Acceptance And Priority Review Of Tinlarebant NDA For Stargardt Disease Type 1, With PDUFA Date Of February 12, 2027Benzinga · Aug 11, 2026, 8:04 PM
Why Is Belite Bio Stock Gaining Monday?Benzinga · Jul 20, 2026, 5:35 PM
Belite Bio Announces Additional Secondary Endpoint Data From Phase 3 DRAGON Trial Of Tinlarebant In Stargardt Disease, Presented At ASRS 2026 In MontréalBenzinga · Jul 20, 2026, 12:06 PM
Belite Bio to Participate in the Piper Sandler Virtual Ophthalmology Investor SymposiumGlobenewswire Inc · Jul 6, 2026, 12:15 PM